Pomerantz LLP is investigating Alibaba Group for potential securities fraud and unlawful business practices following reports that Alibaba illicitly accessed AI technology and failed to prevent illegal pharmaceutical sales on its platform. Alibaba's stock dropped after these revelations and a $600 million settlement with the U.S. Department of Justice over the pharmaceutical violations. The investigation could lead to a class action lawsuit representing affected investors.
Shares of Alibaba, PDD, and JD.com rose on Friday, with Alibaba leading a 3% gain amid a broader uptick in Chinese internet stocks despite a weak overall market. This move appears driven by sector rotation rather than company-specific news, as Alibab...
Alibaba's stock fell 18% after missing Q1 earnings expectations, but this selloff is seen as overdone, leading to an upgrade to Strong Buy. The company's AI Cloud revenue surged 45% year-over-year, with expectations to maintain over 40% growth and im...
